QAGE² research explorer
Institutional discovery views for AQDE oncology, AQGRE genomics, BBB/SOKS, mRNA concepts, cancer research and quantum-theory workflows.
Research sandboxA research-to-market platform and human-approved marketing agent derived from the attached QAGE² MedSuite prototype—designed for evidence-aware positioning, institutional pilots and permission-led growth.
The public experience separates exploratory science from external promotion. It drafts useful materials while keeping evidence status, intended audience and accountable human review visible.
Institutional discovery views for AQDE oncology, AQGRE genomics, BBB/SOKS, mRNA concepts, cancer research and quantum-theory workflows.
Research sandboxGenerates positioning, permission-based email, organic social, webinar copy and a 30-day activation plan locally in the browser.
Human in loopFlags common clinical, safety, regulatory, absolute and comparative phrases before content moves to medical, legal and regulatory review.
Review supportScores and labels below are illustrative interface simulations. They are not clinical performance, validated predictions or regulatory claims.
Variant encoding → pathway graph → quantum-walk concepts → topological-trap analysis → constrained QUBO planning.
Free early access is active through 15 July 2026 at 23:59 Singapore time.
Broad public availability plus segmented, permission-led account development—never indiscriminate bulk email to every organisation or employee.
GitHub Pages launch, founder post, QAGE² walkthrough, pricing deadline and reusable demo clips.
Share through public biotech networks, accelerators, CRO/CDMO partners and responsible-AI communities.
Run an opt-in event on translating exploratory biomedical models into reviewable narratives.
Invite engaged teams through existing relationships and public business channels with human-reviewed copy.
The launch markets a research workflow, not a medicine, diagnosis, therapeutic outcome or clinical decision.
Performance, safety, efficacy, regulatory and comparative claims require an exact source and authorised review.
Do not enter PHI, patient-identifiable information, confidential trial data, credentials or secrets.
The agent drafts only. Human selection, consent assessment, approval, sending and suppression remain outside the public tool.
Free through 15 July 2026; US$10 once from 16 July. No subscription, automatic renewal or hidden recurring charge.
The public research explorer remains free. Q-PGA’s founding-access charge begins after the stated deadline.
Free Q-PGA access runs through 15 July 2026 at 23:59 Singapore time. The one-time US$10 charge starts 16 July 2026 at 00:00 Singapore time. It is not a subscription and does not renew automatically.
No. It drafts local materials only. Every external asset requires human, medical, legal, regulatory and privacy review appropriate to the audience and jurisdiction.
No. GitHub Pages is static. This founding launch uses a soft browser marker after the hosted checkout returns. A production paid service must verify a signed payment webhook and authorise an authenticated account server-side.
Through public product discovery, industry communities, opt-in events, partners, existing relationships and relevant organisation-level outreach. It does not scrape or promise mass unsolicited messaging to every organisation.
Explore the research preview, generate a governed brief and qualify institutional pilots.